Spread is showing as 180-190. At close I could buy 183 and sell 181.5. Lunchtime the bid was higher than the ask. The MM's do play around with this one. |
News soon IMHO |
Well something is bubbling, it's creeping up slowly on small sells, usually a good sign for a leg up. |
Tick tock - just a few weeks of the Q1 '22 reporting period, where the CEO highlighted strong deal flow expected during this period in the last trading update. |
Oncimmune was discussed here on today's Vox 'Stock Picking' videocast (starts 51:20).
www.linkedin.com/posts/paul-hill-a5994116_stocks-to-follow-with-justin-waite-and-paul-activity-6826865195483242496-ww3t |
Another brilliant RNS! This company is seriously going places |
And a few more at £1.60! Looking for £3 a share in 6-12 months |
Took a few more on the drop today, happy to accumulate while it's quiet |
Someone's is keen, some nice lumps coming in |
Looks like a seller held us back last week.. news due now |
Now below the placing price |
Well this is frustrating |
Added again at 180 odd. News on many fronts due |
I feel another top up coming on, cheap! |
Recording and Q&A now available from yesterday |
IMC Useful presentation with useful revene figures - Has been recorded and well worth a listen (imo) if a holder or a potential investor |
Clear takeover target. Premium offer coming soon IMHO |
Latest proactive interview
and ONC also presenting on investor meet later today at 4.30pm |
N+1 Singer
Trading update reaffirms positive outlook
A comprehensive FY’21 (May Y/E) trading statement touts a strong FY’21 outturn in line with our expectations that shows 8x topline growth, building strength in the ImmunoINSIGHTS service business and sets the tone for future upgrades. We leave estimates unchanged, but believe forecasts are prudently pitched with risk to the upside. Notably Investors should take confidence in that management believes that, eight days into the new financial year and a strong start to FY’22, it has visibility on up to 50% of our current FY’22 ImmunoINSIGHTS revenue estimate (£9.4m) and has used today’s statement to reiterate confidence in meeting expectations and delivering maiden profitability in FY’22. Refreshing our valuation analysis implies an intrinsic value of 271p, we reiterate Oncimmune as a Best Idea for 2021... |
Huge growth story unfolding here, I'm expecting 100% share price growth from here within 12 months |
Agree positive update and good to see NHS work picking up. |
Trading Update.
All looks v positive to me.
New contracts to be signed before end August...
"The ImmunoINSIGHTS pipeline of qualified commercial opportunities has continued to grow throughout FY21 and currently stands at more than 160. A number of these opportunities are in late stage legal documentation and, as a consequence, the Company expects to sign these new contracts in Q1 FY22. These studies have been programmed into the Company's forward production schedule, which entails identifying and assigning the resources required to deliver each contract. Of particular note in this schedule are two contracts for major pharmaceutical companies which represent substantial follow-on validation contracts." |
 ("Oncimmune" or the "Company")
Notice of FY21 Trading Update
Oncimmune Holdings plc (AIM: ONC.L), the leading global immunodiagnostics group, announces that it will issue a trading update for the year ended 31 May 2021 on 8 June 2021.
Analyst and investor presentations
Dr Adam M Hill, Chief Executive Officer and Matthew Hall, Chief Financial Officer will host an online presentation for analysts at 11:30am BST on 8 June 2021. For registration details please contact Alexander Davis of FTI Consulting at Alexander.Davis@fticonsulting.com or 020 3727 1000.
Dr Adam M Hill and Matthew Hall will also host a live presentation on Investor Meet Company at 4:30pm BST on 8 June 2021 which will be open to all existing Oncimmune shareholders and potential new investors. Access to Investor Meet Company is free and interested parties are invited to register their attendance on the following link:
Investors who already follow Oncimmune Holdings plc on the Investor Meet Company platform will automatically be invited. Questions can be submitted pre-event via your Investor Meet Company dashboard up until 9:00am BST the day before the meeting or at any time during the live presentation. |
Register to chat with like-minded investors on our interactive forums.
Hot Features
Premium
